$13.92
+0.54 (+4.04%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ORIC is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional
Held by 11 tracked-famous managers (VIKING GLOBAL INVESTORS LP, CITADEL ADVISORS LLC, D. E. Shaw & Co., Inc., Qube Research & Technologies Ltd, MILLENNIUM MANAGEMENT LLC, +6 more) · FINRA short interest 13.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)NCT07723248Radiographic Progression Free Survival assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)Randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel | Metastatic Castration Resistant Prostate Cancer | 600 | Mar 2028 | ≤ 590 d | 2026-07-23 |
| Study of ORIC-944 in Patients With Metastatic Prostate CancerNCT05413421Recommended Phase 2 Dose (RP2D)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets | Metastatic Prostate Cancer | 275 | Jun 2027 | ≤ 315 d | 2026-07-09 |
| ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCNCT06816992Recommended Phase 2 Dose (RP2D)Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: ORIC-114 Dose 1 + amivantamab, ORIC-114 Dose 2 + amivantamab, ORIC-114 Dose 3 + amivantamab | Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC | 76 | Dec 2026 | ≤ 134 d | 2026-04-24 |
| Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationNCT05315700Recommended Phase 2 Dose (RP2D)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: ORIC-114, Chemotherapy drug | Solid Tumors | 350 | Sep 2026 | ≤ 42 d | 2025-08-05 |
| Study of ORIC-533 in Relapsed or Refractory Multiple MyelomaNCT05227144Recommended Phase 2 Dose (RP2D)Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ORIC-533 | Relapsed or Refractory Multiple Myeloma | 31 | 2025-03-03actual | — | 2025-03-20 |
| Effect of Food on the Pharmacokinetics of ORIC-114NCT06012721Maximum plasma concentration (Cmax)Randomized · Open-label · Other | Phase 1 | Completed | Drug: ORIC-114 | Food Effect in Healthy Participants | 32 | 2023-11-23actual | — | 2024-01-19 |
| Study of ORIC-101 in Combination With EnzalutamideNCT04033328Recommended Phase 2 Dose (RP2D)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: IND Withdrawn | Drug: ORIC-101, enzalutamide 40 MG oral capsule [Xtandi] | Prostatic Neoplasms | 41 | 2022-11-22actual | — | 2023-12-15 |
| Study of ORIC-101 in Combination With Anticancer TherapyNCT03928314Part I: Recommended Phase 2 Dose (RP2D)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: IND Withdrawn | Drug: ORIC-101, Nab-paclitaxel | Solid Tumor | 83 | 2022-09-22actual | — | 2023-12-15 |
| Single and Multiple Dose Study of ORIC-101 in Adult Healthy SubjectsNCT03835637Maximum plasma concentration (Cmax)Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: ORIC-101 | Healthy Volunteers | 32 | 2018-07-04actual | — | 2019-02-08 |
| Study of ORIC-101 in Healthy Adult SubjectsNCT03324555Safety and tolerability, as assessed by incidence and severity of adverse events.Open-label · Treatment | Phase 1 | Completed | Drug: ORIC-101 | Healthy Volunteers | 24 | 2017-12-18actual | — | 2018-04-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19